Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine-Reference-Cited by-同舟云学术

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

Published:2009-04-27 Issue:19 Volume:106 Page:7962-7967
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proceedings of the National Academy of Sciences

Author:

Galli G.,Hancock K.,Hoschler K.,DeVos J.,Praus M.,Bardelli M.,Malzone C.,Castellino F.,Gentile C.,McNally T.,Del Giudice G.,Banzhoff A.,Brauer V.,Montomoli E.,Zambon M.,Katz J.,Nicholson K.,Stephenson I.

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference19 articles.

1. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus

2. Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control

3. Strategies for mitigating an influenza pandemic

4. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans

5. Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine

Cited by 228 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo;Biomaterials;2024-10

2. A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models;Vaccine;2024-09

3. Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus;Nature Medicine;2024-07-16

4. Dominant epitopes of cross‐reactive anti‐domain III human antibody response change from early to late convalescence of infection with dengue virus;Journal of Medical Virology;2024-02

5. Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age;Vaccines;2023-09-26